Mohamad Hussein is an Oncology physician affiliated with University of South Florida. OpenAlex indexes 177 publications with 7,143 citations (h-index 40); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13330 Usf Laurel Dr
Tampa, FL 336126601
Telephone
813-974-2201Provider last certified this registry record 31 Mar 2021.
Clinical trials
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: National Cancer Institute (NCI)
- Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
Sponsor: The Cleveland Clinic
- S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20255 payments
- Janssen Scientific Affairs, LLCProgram year20241 payment
- Siemens Medical Solutions USA, Inc.Program year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma
Current Medical Research and Opinion
2015 - Quantification of peptides from immunoglobulin constant and variable regions by LC‐MRM MS for assessment of multiple myeloma patients
PROTEOMICS - CLINICAL APPLICATIONS
2014 - Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Vogelbaum, MD
University of South Florida
Thomas Casale, MD
University of South Florida
Richard Lockey, MD
University of South Florida
Robert Hauser, MD
University of South Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”